News
Obsidian Therapeutics Announces Clinical & Preclinical Presentations at the American Association of Cancer Research Annual Meeting
March 5, 2024
Read MoreObsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy
December 12, 2023
Read MoreObsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments
May 23, 2023
Read MoreABOUT US
We are pioneers in cell and gene therapy
Leading the next generation of engineered therapeutics
Our Platform
Our proprietary
cytoDRiVE platform
Leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule
OBSIDIAN CAREERS
Join Our Team
Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.